Preview

Опухоли женской репродуктивной системы

Расширенный поиск

Оптимальная циторедуктивная хирургия у первичных больных раком яичников III–IV стадий

https://doi.org/10.17650/1994-4098-2010-0-4-103-111

Полный текст:

Аннотация

Представленный обзор литературы посвящен определению роли хирургии в лечении первичных больных раком яичников III– IV стадий. Основные цели исследования: выработка оптимальной тактики выполнения хирургических циторедуктивных вмешательств, анализ возможности их осуществления и оценка риска возникновения послеоперационных осложнений.

Об авторах

Н. Г. Кормош
НИИ клинической онкологии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


К. П. Лактионов
НИИ клинической онкологии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Н. С. Кержковская
НИИ клинической онкологии ГУ РОНЦ им. Н.Н. Блохина РАМН, Москва
Россия


Список литературы

1. Aebi S., Castiglione M. Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(4):21–3.

2. Meigs J.V. Tumors of the female pelvic organs. NY: Macmillan, 1934.

3. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Mongr 1975;421:101–4.

4. Hacker N.F., Berek J.S., Lagasse L.D. et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413–20.

5. Hoskins W.J., Bundy B.N., Thigpen J.T. et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159–66.

6. Piver M.S., Lele S.B., Marchetti D.L. et al. The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988;6:983–9.

7. Guidozzi F., Ball J.H.S. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994;53:326–30.

8. Кормош Н.Г. Геометрия остаточной опухоли у диссеминированных больных раком яичников. VI съезд онкологов и радиологов стран СНГ. Материалы съезда. M., 2010; абстр 1126.

9. Eisenkop S.M., Spirtos N.M. What are the current surgical objectives, strategies, and technical capabilities of gynecologiconcologists treating advanced epithelial ovarian cancer? Gynecol Oncol 2001;82(3):489–97.

10. Ovarian cancer. NCCN Clinical Practice Guidelines in Oncology, 2010. V.2. www.nccn.org

11. Stoeckle E., Paravis P., Floquet A. et al. Number of residual nodules better than size, defines optimal surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer 2004;14(5):779–87.

12. Hoskins W.J., Bundy B.N., Thigpen J.T. et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. Gynecol Oncol 1992;47: 159–66.

13. Bristow R.E., Tomacruz R.S., Armstrong D.K. et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20(5):1248–59.

14. Bristow R.E., Montz F.J., Lagasse L.D. et al. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72(3):278–87.

15. Winter W.E.3rd, Maxell G.L., Tian C. et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:3621–7.

16. Winter W.E.3rd, Maxell G.L, Tian C. et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2008;26:83–9.

17. Salani R., Axtell A., Gerard M. et al. Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2008;108:271–5.

18. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y. et al. The effect of maximum surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 2008;108:276–81.

19. Covens A.L. A critique of surgical cytoreduction in advanced ovarian cancer. Gynecol Oncol 2000;78:269–74.

20. Burghardt E., Pickel H., Lahousen M., Stettner H. Pelvic lymphadenectomy in operative treatment of ovarian cancer. Am J Obstet Gynecol 1986;155:315–9.

21. Maggioni A., Benedetti Panici P., Dell Anna T. et al. Randomized study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 2006;95:699–704.

22. Onda T., Yoshikawa H., Yasugi T. et al. Patients with ovarian carcinoma upstaged to stage ШС after systematic lymphadenectomy have similar survival to stage l/II patients and superior survival to other stage III patients. Cancer 1998;83:1555–60.

23. du Bois A., Reuss A., Harter P. et al. Potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 2010;28(10):1733–9.

24. Panici P.B., Maggioni A., Hacker N. et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97(8):560–6.

25. Hacker N.F., Valmadre S., Robertson G. Management of retroperitoneal lymph nodes in advanced ovarian cancer. J Gynecol Cancer 2008;18(1):7–10.

26. Nelson B.E., Rosenfield A.T., Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993;11:166–72.

27. Chi D.S., Venktraman E.S., Masson V. et al. The ability of preoperative serum CA125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77: 227–31.

28. Axtell A.E., Lee M.H., Bristow R.E. et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 2007;25(4):384–9.

29. Chi D.S., Franklin C.C., Levine D.A. et al. Improved optimal cytoreduction rates for stage IIIC and IV epithelial ovarian, fallopian tube, primary peritoneal cancer: A change in surgical approach. Gynecol Oncol 2004;94:650–4.

30. Hou J.Y., Kelly M.G., Yu H. et al. Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 2007;105:211–7.

31. Fagotti A., Ferrandina G., Fanfani F. et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13:1156–61.

32. Angioli R., Palaia I., Zullo M.A. et al. Diagnostic open laparoscopy in the management of advanced ovarian cancer. Gynecol Oncol 2006;100(3):455–61.

33. Копнин Б.П. Мишени действия онкогенов и опухолевых супрессоров: ключ к пониманию базовых механизмов канцерогенеза. Биохимия 2000;65:5–33.

34. Darcy K.M., Birrer M.J. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol 2010;117(3):429–39.

35. Sabatier R., Finetti P., Cervera N. Gene expression profiling and prediction of clinical outcome in ovarian cancer. Critic Rev Oncol/Hematol 2009;72(2):98–109.

36. Berchuck A., Iversen E.S., Lancaster J.M. et al. Prediction of optimal versus suboptimal cytoreduction of advanced- stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004;190:910–25.

37. Gerestein C.G, Damhuisb R.A.M., Burgerc C.W., Kooia G.S. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: A systematic review. Gynecol Oncol 2009;114(3):523–7.

38. Aletti G.D., Santillan A., Eisenhauer E.L. et al. A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short- term outcomes for ovarian cancer using a risk-adjusted model. Gynecol Oncol 2007;107(1):99–106.

39. Gerestein C.G., Damhuis R.A.M., de Vries M. et al. Causes of postoperative2 mortality after surgery for ovarian cancer. Eur J Cancer 2009;45(16):2799–803.

40. Gerestein C.G., Nieuwenhuyzen-de Boer G.M, EijkemansM.J. et al. Prediction of 30-day morbidity after

41. primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer 2010;46(1):102–9.

42. Van der Burg M.E., van Lent M., Buyse M. et al. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629–34.

43. Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 2003;13:163–8.

44. Vergote I., Tropacup C.G., Amant F. et al. EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIc–IV ovarian, fallopian tube and peritoneal cancer (OvCa). International Gynecologic Cancer Society 2008 Meeting: abstr 1767. 44.http://www.nejm.org/doi/ suppl/10.1056/NEJMoa0908806/suppl_ file/nejmoa0908806_appendix.pdf

45. Vergote I., Tropé C.G., Amant F., Kristensen G.B. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New Engl J Med 2010;363:943–53.

46. Bristow R.E., Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 2006;103(3):1070–6.

47. Hunter R.W., Alexander N.D.E., Soutter W.P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol 1992;166:504–11.


Для цитирования:


Кормош Н.Г., Лактионов К.П., Кержковская Н.С. Оптимальная циторедуктивная хирургия у первичных больных раком яичников III–IV стадий. Опухоли женской репродуктивной системы. 2010;(4):103-111. https://doi.org/10.17650/1994-4098-2010-0-4-103-111

For citation:


Kormosh N.G., Laktionov K.P., Kerzhkovskaya N.S. Optimal cytoreduction for advanced epithelial ovarian cancer. Tumors of female reproductive system. 2010;(4):103-111. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-4-103-111

Просмотров: 169


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1994-4098 (Print)
ISSN 1999-8627 (Online)